Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy

NCT03088813 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT03088813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03088813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Completed
Start date
April 25, 2018
Completion date
July 27, 2023
Enrollment
491 (actual)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer